Drug Trial Radar · NCT06349473
A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Two Participants Groups (Part A: Healthy Participants, and Part B: Participants With Hemophilia A or Hemophilia B or Factor VII Deficiency)
Last checked: Nov 19, 2026Latest source record: Jul 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
31
Planned (sponsor's estimate)
Start
May 10, 2024
Primary completion
Sep 28, 2026
Study completion Sep 28, 2026
Sponsor
- Lead sponsor
- Equilibra Bioscience LLCIndustry
- Sponsor type
- Industry
- First posted
- Apr 5, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamic (PD) of SR604 in healthy participants (Part A) and to evaluate the safety, tolerability, PK, PD, and efficacy of SR604 in participants with Hemophilia A or Hemophilia B, or Factor VII (FVII) deficiency, with or without inhibitors (Part B).
Conditions
- Healthy Participants
- Hemophilia A
- Hemophilia B
- Factor VII Deficiency
Interventions
SR604Drug
SR604 will be administered as SC injection.
PlaceboDrug
Placebo will be administered as single SC injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Parts A and B: Number of Participants with Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)Time frame: Part A: From Baseline (Day 1) up to Day 57; Part B: From Baseline (Day 1) up to 3 months
- Parts A and B: Number of Participants with Clinical Abnormal Changes in Coagulations MarkersTime frame: Part A: From Baseline (Day 1) till Day 57; Part B: From Baseline (Day 1) till Day 90
Locations
10 sites in 2 countries. Site status is shown where the registry gives one.
California Clinical Trials Medical Group (CCTMG)
Glendale, California · Completed
Children's Hospital Los Angeles
Los Angeles, California · Recruiting
Rush University Medical Center
Chicago, Illinois · Recruiting
LA Center for Bleeding and Clotting Disorders - Metairie
Metairie, Louisiana · Recruiting
University of Michigan Hospitals - Michigan Medicine
Ann Arbor, Michigan · Recruiting
Washington University School of Medicine
St Louis, Missouri · Recruiting
Brody School of Medicine at East Carolina University
Greenville, North Carolina · Not yet recruiting
Penn State Milton S Hershey Medical Center Pediatrics
Hershey, Pennsylvania · Recruiting
Perelman Center for Advanced Medicine (PCAM)- Penn Blood Disorders Program
Philadelphia, Pennsylvania · Recruiting
McMaster University Medical Centre, Hamilton Health Sciences
Hamilton, Ontario, Canada · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.